Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).
Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).
Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).
Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.
Renin‐angiotensin system inhibition showed no clear difference in kidney failure or doubling of SCr compared with placebo or no treatment (low certainty).
Renin‐angiotensin system inhibition showed no clear difference in remission of proteinuria: complete remission compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to 2 years' corrected age))** compared with placebo (outcomes (moderate certainty).
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).